Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules

Author(s): Caroline Descôteaux, Kevin Brasseur, Valérie Leblanc, Eric Asselin, Gervais Bérubé

Journal Name: Medicinal Chemistry

Volume 11 , Issue 8 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The search for new specific chemotherapeutic drugs designed to minimize the toxic side effects resulting from chemotherapy is still a subject of intense research. The objective of the current study was to design a non-steroidal-platinum(II) derivative that would target the estrogen receptor alpha (ERα) without triggering estrogenic cell proliferation. For this purpose, the amino acid L-tyrosine was modified and attached to a cisplatin analog. Hence, the L-tyrosine portion of the molecule could possibly act as a transporter to target the ER#945; protein and, by doing so concentrate the cytotoxic moiety to hormone-dependent breast cancer cells. Herein, we describe three different alternative methodologies that were used to make these new anticancer molecules. The L-tyrosine-Pt(II) hybrid 5b was made in four steps with 36% overall yield by the first method, in six steps with 11% overall yield by the second method and, in four steps with 23% overall yield by the third method. Preliminary biological activity on breast cancer cell lines indicated that the final hybrids (5a and 5b) were unfortunately inactive but their platinum(II) precursors (14a and 14b) showed activity similar to that of cisplatin.

Keywords: L-tyrosine, platinum(II), anticancer agent, breast cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 28 October, 2015
Page: [717 - 724]
Pages: 8
DOI: 10.2174/1573406411666150504123750
Price: $65

Article Metrics

PDF: 28
PRC: 1